Previous 10 | Next 10 |
ASHBURN, Va., May 24, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announces that its open label study evaluating QRX003 as a treat...
2023-05-12 16:43:09 ET Quoin Pharmaceuticals, Ltd. (QNRX) Q1 2023 Earnings Conference Call May 09, 2023, 08:30 AM ET Company Participants Gordon Dunn - Chief Financial Officer Michael Myers - Co-Founder, Chairman, Chief Executive Officer and Director Conference...
2023-05-08 17:04:33 ET Quoin Pharmaceuticals press release ( NASDAQ: QNRX ): Q1 GAAP EPS of -$0.34 misses by $0.06 . For further details see: Quoin Pharmaceuticals GAAP EPS of -$0.34 misses by $0.06
First patient dosed in Quoin’s single arm, open label clinical trial in Netherton Syndrome patients currently receiving off-label systemic therapy Recruitment and dosing continue in Quoin’s ongoing double blinded, placebo-controlled study of QRX003 for Netherton Syndrome ...
ASHBURN, Va., May 02, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company intends to release its first qua...
ASHBURN, Va., March 21, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces the dosing of the first patient in its open la...
2023-03-09 14:27:02 ET Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2022 Earnings Conference Call March 9, 2023 08:30 ET Company Participants Gordon Dunn - Chief Financial Officer Michael Myers - Chief Executive Officer Conference Call Participants James Molloy ...
2023-03-08 17:19:48 ET Quoin Pharmaceuticals press release ( NASDAQ: QNRX ): Q4 GAAP EPS of -$0.41 beats by $0.19 . For further details see: Quoin Pharmaceuticals GAAP EPS of -$0.41 beats by $0.19
Quoin announced dosing of first patient in double blinded clinical study to evaluate QRX003 for Netherton Syndrome Quoin announced initiation of a second clinical trial to evaluate QRX003 in Netherton Syndrome patients currently receiving off-label systemic therapy Continued adv...
ASHBURN, Va., March 02, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company intends to release its 2022 f...
News, Short Squeeze, Breakout and More Instantly...
Quoin Pharmaceuticals Ltd. Company Name:
QNRX Stock Symbol:
NASDAQ Market:
Quoin Pharmaceuticals Ltd. Website:
Clinical site to be Opened in Saudi Arabia Site Currently Treating Netherton Patients Who Are Eligible for Recruitment into Quoin Studies Experienced Local Clinical Research Organization Has Been Engaged Plans for the Opening of Additional International Sites at an Advan...
ASHBURN, Va., June 25, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announces that it will be a Bronze Sponsor for the Foundat...
Agreement will focus on the development of novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare and orphan diseases UCC’s proprietary dissolvable microneedles technology and other approaches will be utilized to optimize the local delivery ...